Skip to main content
Michael Hurwitz, MD, Oncology, New Haven, CT, Yale-New Haven Hospital

MichaelEHurwitzMD

Oncology New Haven, CT

Assistant Professor of Medicine, Division of Oncology, Yale University School of Medicine

Dr. Hurwitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hurwitz's full profile

Already have an account?

  • Office

    333 Cedar St
    Yale University School Of Medicine
    New Haven, CT 06510
    Phone+1 203-200-4822
    Fax+1 203-200-2099
  • Is this information wrong?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2004
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1998 - 2000
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1998

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 2010 - 2024
  • MA State Medical License
    MA State Medical License 2000 - 2010

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • CAR T Cell Therapy May Eliminate Tumor Cells Missed by Surgery
    CAR T Cell Therapy May Eliminate Tumor Cells Missed by SurgeryFebruary 9th, 2023
  • Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium
    Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers SymposiumFebruary 19th, 2017
  • 'We're Not There yet': CAR T-cell Therapy for Renal Cell Carcinoma
    'We're Not There yet': CAR T-cell Therapy for Renal Cell CarcinomaNovember 17th, 2023

Grant Support

  • Screening Of Synthetic Lethality With C. Elegans RBNational Cancer Institute2004–2008

Hospital Affiliations